8
Participants
Start Date
June 30, 2007
Primary Completion Date
April 30, 2008
Study Completion Date
April 30, 2008
Cisplatin
Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
Etoposide
Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
Radiotherapy
Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
Sorafenib
Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months
Oncology Partners Network, Cincinnati
Indiana University Cancer Center, Indianapolis
Center for Cancer Care at Goshen Health System, Goshen
Northern Indiana Cancer Research Consortium, South Bend
Fort Wayne Oncology & Hematology, Inc, Fort Wayne
Medical Consultants, P.C., Muncie
Horizon Oncology Center, Lafayette
Medical & Surgical Specialists, LLC, Galesburg